- Home
- MERC vs TLSA Comparison
MERC vs TLSA Comparison
Compare MERC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- TLSA
- Stock Information
- Founded
- MERC 1968
- TLSA 2013
- Country
- MERC Canada
- TLSA United Kingdom
- Employees
- MERC N/A
- TLSA N/A
- Industry
- MERC Paper
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- TLSA Health Care
- Exchange
- MERC Nasdaq
- TLSA Nasdaq
- Market Cap
- MERC 190.9M
- TLSA 196.1M
- IPO Year
- MERC 1987
- TLSA 2000
- Fundamental
- Price
- MERC $1.60
- TLSA $1.73
- Analyst Decision
- MERC Hold
- TLSA
- Analyst Count
- MERC 3
- TLSA 0
- Target Price
- MERC $3.00
- TLSA N/A
- AVG Volume (30 Days)
- MERC 675.0K
- TLSA 214.9K
- Earning Date
- MERC 11-06-2025
- TLSA 05-06-2025
- Dividend Yield
- MERC 13.39%
- TLSA N/A
- EPS Growth
- MERC N/A
- TLSA N/A
- EPS
- MERC N/A
- TLSA N/A
- Revenue
- MERC $1,906,971,000.00
- TLSA N/A
- Revenue This Year
- MERC N/A
- TLSA N/A
- Revenue Next Year
- MERC $13.33
- TLSA N/A
- P/E Ratio
- MERC N/A
- TLSA N/A
- Revenue Growth
- MERC N/A
- TLSA N/A
- 52 Week Low
- MERC $1.55
- TLSA $0.63
- 52 Week High
- MERC $8.28
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- MERC 22.81
- TLSA 39.69
- Support Level
- MERC $1.55
- TLSA $1.60
- Resistance Level
- MERC $1.77
- TLSA $1.81
- Average True Range (ATR)
- MERC 0.16
- TLSA 0.12
- MACD
- MERC -0.02
- TLSA -0.01
- Stochastic Oscillator
- MERC 5.69
- TLSA 27.19
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.